Paul Owen has been appointed as Chief Executive Officer of YourBio Health, a pioneer in remote blood collection technology, and CEO-Partner of Flagship Pioneering, a bioplatform innovation company.

Owen joins YourBio Health and Flagship after a corporate leadership and strategic planning career spanning more than 35 years. He was most recently Board Director and President of Oncodea, an early cancer detection company, and a Managing Partner for Trusted Health Advisors, overseeing diagnostics, companion diagnostics, population health, and digital health. He has previously held leadership roles across digital health and health care solutions including with imaware, OneOme, and Mayo Medical Laboratories.

“Paul’s strategic vision and leadership will be instrumental as YourBio Health continues its mission to humanize, decentralize, and transform the blood collection process, which we envision serving the entire healthcare industry,” said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering. “We are pleased to welcome him to the Flagship leadership network and look forward to his impact on YourBio Health.”

YourBio’s Touch-Activated Phlebotomy (TAP) device is the first push-button blood collection technology. Using microneedles to achieve virtually painless blood draws, TAP products are used today in clinical trial, diagnostic, and wellness settings and enable easy-to-use and reliable at-home blood collection. The Flagship-founded company has existing partnerships with biopharmaceutical companies, leading genetic companies, and academic research hospitals. Since commercial launch, TAP devices have been used in multiple clinical trials and in millions of blood collections.

“I am pleased to have the chance to lead YourBio Health and collaborate with the exceptional and forward-thinking leadership teams at both companies,” said Owen. “Throughout my career, I’ve seen the challenges created by phlebotomy – the pain, discomfort and logistical challenges for trial sponsors, patients, clinicians and healthcare organizations. I look forward to scaling and growing YourBio so this technology can help eliminate those challenges and deliver a better-quality patient experience.”

The company also announced concurrent appointments to its leadership team, including:

• Michael Mina, M.D., Ph.D. as Chief Scientific Officer
• Chester Robson D.O., as Chief Medical Officer
• Thomas Briggs as Chief Growth Officer